NR1H4 and metabolic dysfunction-associated steatohepatitis: Vonafexor (100 mg/d for 12 weeks), a 2nd generation, highly selective non-steroidal FXR agonist, has recently been found to improve liver steatosis, the fibro-inflammation marker cT1 levels, and estimated glomerular filtration rate (eGFR) in NASH patients with normal or mildly decreased eGFR [65].